v3.25.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
The following table presents selected financial information with respect to the Company’s single operating segment for the years ended:

Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Collaboration revenue$1,950 $94,694 $22,508 $153,814 
Less:
Research and development expenses
Direct research and development expenses
ENTR-601-446,158 2,232 10,892 5,511 
ENTR-601-454,576 588 7,435 3,126 
ENTR-601-502,040 3,216 2,732 5,859 
ENTR-601-512,855 46 3,681 116 
Collaboration services527 6,631 1,403 7,384 
Other preclinical and discovery1,224 2,028 2,481 3,939 
Unallocated research and development expenses
Personnel related (including stock-based compensation)13,231 9,912 25,987 19,812 
Facility related and other7,266 7,382 15,340 14,896 
Total research and development expenses37,877 32,035 69,951 60,643 
General and administrative expenses10,922 9,236 21,196 18,635 
Interest and other income3,924 4,366 8,365 8,580 
Provision for income taxes178 2,758 178 4,589 
Net (loss) income
$(43,103)$55,031 $(60,452)$78,527